Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Stock Watch: Sanofi, Pfizer And The Aftermath Of Acquisitions

Typical And Atypical Biotech Stock Responses

Mar 27 2023

• By Andy Smith

Andy Smith — ANDY SMITH OFFERS A LIFE SCIENCE INVESTOR'S PERSPECTIVE ON BIOPHARMA BUSINESS

Related Content

Stock Watch: Funding Biotech In A Hostile Environment

Mar 14 2023

Sanofi Goes All In For Type 1 Diabetes With Provention Buy

Mar 13 2023

Pfizer Pays $43bn For Seagen With Goal Of Rapidly, Globally Advancing ADCs

Mar 13 2023

Stock Watch: Swelling Obesity Sales Boost Post-Pandemic Diabetes Drug Growth

Dec 06 2022

Blenrep US Withdrawal Is A Big Blow To GSK’s Blockbuster Hopes

Nov 22 2022

Biogen ALS Drug Granted FDA Priority Review, Triggering Aduhelm Déjà Vu

Jul 26 2022

Related Companies

Sanofi

Provention Bio, Inc.

Eli Lilly and Company

Novo Nordisk A/S

Lexicon Pharmaceuticals, Inc.

MannKind Corporation

Pfizer Inc.

Seagen Inc.

Merck & Co., Inc.

AstraZeneca PLC

Daiichi Sankyo Co., Ltd.

GSK plc

Tesaro, Inc.

Jounce Therapeutics, Inc.

Redx Pharma Plc

Heron Therapeutics, Inc.

Corvus Pharmaceuticals, Inc.

Aptevo Therapeutics Inc.

Additional Topics

M & A Commercial Companies Strategy Stock Watch BioPharmaceutical

More from Stock Watch

More from Business

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window